Sofosbuvir and Daclatasvir for treatment of Hepatitis-C in patients undergoing hemodialysis.

Not Applicable

• Conditions: Condition 1: Chronic Viral Hepatitis-C. Condition 2: Chronic kidney disease, stage 5.; Chronic viral hepatitis C; Chronic kidney disease, stage 5

• Registration Number: IRCT20170614034526N3
• Lead Sponsor: Jinnah Hospital, Lahore

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 25 March 2019

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 36

Inclusion Criteria

Male & Female (non-pregnant)
being at the age of 18 years and over
End stage renal disease patients undergoing maintenance hemodialysis detected with HCV RNA by PCR.

Exclusion Criteria

Patients having co-infection with HBV, HIV.
Patients with decompensated cirrhosis and terminal illness.
Patients hypersensitive to any of the ingredients of treatment drugs.

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Sustained Virologic Response (SVR) assessed. Timepoint: 24th week after start of treatment. Method of measurement: HCV RNA- PCR.

Secondary Outcome Measures

Name	Time	Method
End of Treatment response (ETR). Timepoint: 12th week of start of treatment. Method of measurement: HCV RNA-PCR.